How COBENFY™ works

(xanomeline and trospium chloride)

Actor portrayals.

COBENFY is not an antipsychotic. It works differently

See how COBENFY works to treat schizophrenia

Graphic with COBENFY logo, generic name, dosages, and tagline

COBENFY is the first and only FDA-approved schizophrenia medicine that is thought to work by activating small proteins in the brain called muscarinic acetylcholine receptors.

COBENFY is a different approach to schizophrenia treatment. COBENFY is a unique combination of 2 medicines: xanomeline and trospium chloride.

Icon of a magenta-colored brain with white sparks in the center

Xanomeline (Za-NO-muh-leen) is thought to activate muscarinic receptors in your brain to help adjust important chemical messengers related to your schizophrenia symptoms.

+

Outline of a person with arms spread out in the center of a navy blue circle

Trospium (TRO-spee-um) chloride may help prevent xanomeline from working outside your brain so that other parts of your body are less likely to be impacted.

The exact way COBENFY works is not fully understood.

quote
Brunette woman in a light blue shirt with a hand on a laptop looks into the camera

Education is very important. Taking an active role in your journey is the way to go.

Chayilee lives with schizophrenia, is paid by BMS, and not on COBENFY.

Kelsey is paid by BMS and not on COBENFY.



Cobenfy, Cobenfy Cares, and the Cobenfy logo are trademarks of Karuna Therapeutics, Inc., a Bristol Myers Squibb company.
© 2025 Bristol-Myers Squibb Company. 
1629-US-2500035 03/25
This website is intended for U.S. residents 18 years of age or older.